Sector News

UCB acquires new campus to support UK operations

October 24, 2020
Life sciences

Belgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK.

The acquisition of the site in Windlesham, Surrey is expected to be completed in November 2020, and reflects UCB’s commitment to retain the UK as one of its three global hubs for research and development alongside Belgium and the US.

“I am delighted to have signed an agreement to secure this new campus for our UK hub, from which our scientists will be able to continue to develop their extensive collaborations with some of the most innovative universities, biotechs and medical research charities, bringing even greater benefit for patients,” said Jean-Christophe Tellier, chief executive officer of UCB.

UCB has projected its investment in the UK – including the new site – to be more than £1bn over five years, with the transition to this new facility set to support over 650 high-value jobs in scientific research, translational medicine, clinical development, early manufacturing and commercial roles.

Following the completion of the acquisition, the campus will undergo refurbishment prior to UCB relocating from its current UK headquarters in Slough, Berkshire.

The refurbishment will also enable UCB to execute its research plan to develop innovative treatments for patients, including gene therapies and translational medicines, as well as development of its antibody discovery platforms.

“This new UK site will not only support our ambitions for future drug discovery but will be well-placed to enable us to achieve our 2030 global sustainability goals and provides an environment which supports the physical and mental wellbeing of our people – essential to helping us thrive,” added Tellier.

By Lucy Parsons

Source: pharmatimes.com

 

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach